VCYT
VERACYTE, INC.
- Latest sale
- $161k
- Sep 21 · Routine
- Form 4 sales
- 219
- On record
- Form 144 notices
- 17
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualJun 4 2026
Sold 13,975 shares at $50.07 ($700k)
Leite John, Global Chief Commercial Off
10b5-1 planSold 9.6% of holdings ($7.3M position)132,305 shares left5x usual sizeFiling
- 2 Form 4 saleRoutineJun 18 +14 days
Sold 3,729 shares at $52.89 ($197k)
Eastham Karin, Director
10b5-1 planSold 19.8% of holdings ($996k position)15,097 shares left0.4x usual sizeFiling
- 3 Form 4 saleRoutineSep 1 +75 days
Sold 1,864 shares at $42.97 ($80k)
Bhanji Muna, Director
10b5-1 planSold 4.2% of holdings ($1.9M position)42,718 shares leftFiling
- 4 Form 4 saleRoutineSep 4 +3 days
Sold 13,110 shares at $43.05 ($564k)
Febbo Phillip G., Chief Scientific & Med Officer
10b5-1 planSold 9% of holdings ($6.3M position)133,048 shares left1.6x usual sizeFiling
- 5 Form 4 saleRoutineSep 4 same day
Sold 3,652 shares at $43.10 ($157k)
Chambers Rebecca, Chief Financial Officer
10b5-1 planSold 2.2% of holdings ($7.3M position)166,025 shares left0.5x usual sizeFiling
- 6 Form 4 saleRoutineSep 4 same day
Sold 3,254 shares at $43.09 ($140k)
McGuire Annie, EVP, General Counsel
10b5-1 planSold 2.4% of holdings ($5.8M position)131,160 shares left0.7x usual sizeFiling
- 7 Form 4 saleRoutineSep 14 +10 days
Sold 5,000 shares at $40.95 ($205k)
Holstein Jens, Director
10b5-1 planSold 15.4% of holdings ($1.3M position)27,471 shares leftFiling
- 8 Form 4 saleRoutineSep 21 +7 days
Sold 4,015 shares at $40.00 ($161k)
Leite John, Global Chief Commercial Off
10b5-1 planSold 3.1% of holdings ($5.1M position)124,329 shares left1.4x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (236)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Leite John | Global Chief Commercial Off | Form 4 sale | 4,015 | $161k | 3.1% | Routine | SEC |
| Sep 14, 2026 | Holstein Jens | Director | Form 4 sale | 5,000 | $205k | 15.4% | Routine | SEC |
| Sep 4, 2026 | McGuire Annie | EVP, General Counsel | Form 4 sale | 3,254 | $140k | 2.4% | Routine | SEC |
| Sep 4, 2026 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 3,652 | $157k | 2.2% | Routine | SEC |
| Sep 4, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | Form 4 sale | 13,110 | $564k | 9.0% | Routine | SEC |
| Sep 1, 2026 | Bhanji Muna | Director | Form 4 sale | 1,864 | $80k | 4.2% | Routine | SEC |
| Jun 18, 2026 | Eastham Karin | Director | Form 4 sale | 3,729 | $197k | 19.8% | Routine | SEC |
| Jun 4, 2026 | Leite John | Global Chief Commercial Off | Form 4 sale | 13,975 | $700k | 9.6% | Unusual | SEC |
| Jun 4, 2026 | McGuire Annie | EVP, General Counsel | Form 4 sale | 3,176 | $158k | 2.3% | Routine | SEC |
| Jun 4, 2026 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 3,561 | $177k | 2.0% | Routine | SEC |
| Jun 4, 2026 | Stapley Marc | Chief Executive Officer | Form 4 sale | 138,051 | $6.9M | 23.9% | Unusual | SEC |
| May 22, 2026 | Wygant Jonathan | VP, Chief Accounting Officer | Form 4 sale | 24,000 | $1.1M | 34.6% | Unusual | SEC |
| May 20, 2026 | Epstein Robert S | Director | Form 4 sale | 10,000 | $440k | 16.0% | Routine | SEC |
| May 6, 2026 | McGuire Annie | SVP, General Counsel | Form 4 sale | 10,204 | $398k | 6.6% | Routine | SEC |
| Mar 4, 2026 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 5,260 | $185k | 4.7% | Routine | SEC |
| Mar 4, 2026 | McGuire Annie | SVP, General Counsel | Form 4 sale | 6,658 | $237k | 6.6% | Routine | SEC |
| Mar 4, 2026 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 18,341 | $663k | 12.3% | Routine | SEC |
| Mar 4, 2026 | Stapley Marc | Chief Executive Officer | Form 4 sale | 45,523 | $1.6M | 11.3% | Unusual | SEC |
| Mar 2, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | Form 4 sale | 13,425 | $485k | 10.3% | Routine | SEC |
| Dec 16, 2025 | McGuire Annie | SVP, General Counsel | Form 4 sale | 10,739 | $463k | 13.7% | Unusual | SEC |
| Dec 5, 2025 | Eastham Karin | Director | Form 4 sale | 20,000 | $909k | 59.6% | Routine | SEC |
| Dec 4, 2025 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 1,278 | $61k | 1.5% | Routine | SEC |
| Dec 4, 2025 | McGuire Annie | SVP, General Counsel | Form 4 sale | 1,422 | $67k | 1.8% | Routine | SEC |
| Dec 4, 2025 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 13,278 | $622k | 10.8% | Routine | SEC |
| Dec 4, 2025 | Stapley Marc | Chief Executive Officer | Form 4 sale | 7,668 | $361k | 2.4% | Routine | SEC |
| Nov 25, 2025 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 2,808 | $140k | 3.2% | Routine | SEC |
| Nov 25, 2025 | Jones Evan/ Fa | Director | Form 4 sale | 1,106 | $56k | 3.6% | Routine | SEC |
| Nov 20, 2025 | Holstein Jens | Director | Form 4 sale | 10,000 | $424k | 26.9% | Routine | SEC |
| Nov 10, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Form 4 sale | 10,920 | $450k | 22.0% | No plan | SEC |
| Nov 5, 2025 | McGuire Annie | SVP, General Counsel | Form 4 sale | 6,466 | $259k | 7.2% | Routine | SEC |
| Nov 5, 2025 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 7,000 | $287k | 5.3% | Routine | SEC |
| Nov 5, 2025 | Eastham Karin | Director | Form 4 sale | 9,674 | $387k | 41.6% | Routine | SEC |
| Nov 5, 2025 | Jones Evan/ Fa | Director | Form 4 sale | 43,196 | $1.9M | 58.6% | Unusual | SEC |
| Oct 6, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Form 4 sale | 8,349 | $301k | 8.3% | Routine | SEC |
| Oct 1, 2025 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 2,539 | $89k | 2.8% | Routine | SEC |
| Oct 1, 2025 | McGuire Annie | SVP, General Counsel | Form 4 sale | 2,160 | $76k | 2.4% | Routine | SEC |
| Oct 1, 2025 | Epstein Robert S | Director | Form 4 sale | 21,473 | $753k | 25.6% | Routine | SEC |
| Sep 19, 2025 | McGuire Annie | SVP, General Counsel | Form 4 sale | 2,283 | $77k | 2.4% | Routine | SEC |
| Sep 4, 2025 | Stapley Marc | Chief Executive Officer | Form 4 sale | 7,667 | $233k | 2.2% | Routine | SEC |
| Jun 13, 2025 | Eastham Karin | Director | Form 4 sale | 4,590 | $122k | 24.8% | Routine | SEC |
| Jun 13, 2025 | Bhanji Muna | Director | Form 4 sale | 4,589 | $122k | 13.3% | Routine | SEC |
| Jun 4, 2025 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 2,809 | $76k | 2.9% | Routine | SEC |
| Mar 7, 2025 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 7,411 | $235k | 6.9% | Routine | SEC |
| Mar 4, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Form 4 sale | 8,037 | $268k | 8.9% | Routine | SEC |
| Mar 4, 2025 | Stapley Marc | Chief Executive Officer | Form 4 sale | 52,697 | $1.8M | 16.4% | Routine | SEC |
| Mar 4, 2025 | McGuire Annie | SVP, General Counsel | Form 4 sale | 1,142 | $38k | 1.6% | Routine | SEC |
| Feb 27, 2025 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 5,746 | $194k | 6.8% | Unusual | SEC |
| Feb 3, 2025 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 527 | $23k | 0.5% | Routine | SEC |
| Jan 2, 2025 | Eastham Karin | Director | Form 4 sale | 10,000 | $403k | 35.1% | Routine | SEC |
| Dec 13, 2024 | Stapley Marc | Chief Executive Officer | Form 4 sale | 5,590 | $243k | 1.8% | Routine | SEC |
| Dec 13, 2024 | Stapley Marc | Director, Officer | Form 144 notice | 5,590 | $248k | Notice | SEC | |
| Dec 5, 2024 | Febbo Phillip G. | Officer | Form 144 notice | 1,311 | $58k | Notice | SEC | |
| Dec 4, 2024 | Febbo Phillip G. | Chief Scientific & Med Officer | Form 4 sale | 3,934 | $173k | 4.6% | Routine | SEC |
| Dec 4, 2024 | McGuire Annie | SVP, General Counsel | Form 4 sale | 18,699 | $823k | 20.4% | Routine | SEC |
| Dec 4, 2024 | Febbo Phillip G. | Officer | Form 144 notice | 2,623 | $115k | Notice | SEC | |
| Dec 4, 2024 | McGuire Annie | Officer | Form 144 notice | 18,699 | $816k | Notice | SEC | |
| Dec 3, 2024 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 1,050 | $45k | 1.4% | No plan | SEC |
| Dec 3, 2024 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 7,000 | $303k | 5.8% | Routine | SEC |
| Dec 3, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | Form 4 sale | 956 | $41k | 2.3% | No plan | SEC |
| Dec 3, 2024 | Chambers Rebecca | Officer | Form 144 notice | 7,527 | $332k | Notice | SEC | |
| Dec 3, 2024 | Leite John | Officer | Form 144 notice | 1,050 | $46k | Notice | SEC | |
| Nov 27, 2024 | Wygant Jonathan | VP, Chief Accounting Officer | Form 4 sale | 5,032 | $216k | 10.6% | No plan | SEC |
| Nov 19, 2024 | Eastham Karin | Director | Form 4 sale | 14,731 | $565k | 44.3% | Routine | SEC |
| Nov 12, 2024 | Chambers Rebecca | Chief Financial Officer | Form 4 sale | 15,275 | $586k | 10.9% | Routine | SEC |
| Nov 12, 2024 | Epstein Robert S | Director | Form 4 sale | 15,000 | $575k | 25.2% | Routine | SEC |
| Sep 19, 2024 | Jones Evan/ Fa | Director | Form 4 sale | 5,173 | $182k | 100.0% | Routine | SEC |
| Sep 4, 2024 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 5,479 | $163k | 6.7% | Routine | SEC |
| Aug 13, 2024 | Jones Evan/ Fa | Director | Form 4 sale | 47,845 | $1.5M | 58.2% | Unusual | SEC |
| Aug 9, 2024 | Jones Evan/ Fa | Director | Form 4 sale | 1,778 | $53k | 3.7% | Routine | SEC |
| Aug 7, 2024 | Holstein Jens | Director | Form 4 sale | 5,000 | $145k | 15.2% | Routine | SEC |
| Aug 7, 2024 | Jones Evan/ Fa | Director | Form 4 sale | 5,108 | $155k | 10.2% | Routine | SEC |
| Jul 16, 2024 | Eastham Karin | Director | Form 4 sale | 7,500 | $188k | 18.4% | Routine | SEC |
| Jul 16, 2024 | Leite John | Chief Commercial Officer-CLIA | Form 4 sale | 1,277 | $32k | 1.5% | Routine | SEC |
| Jul 16, 2024 | Holstein Jens | Director | Form 4 sale | 5,000 | $123k | 13.2% | Routine | SEC |
| Jun 11, 2024 | Eastham Karin | Director | Form 4 sale | 3,870 | $80k | 11.7% | Routine | SEC |
| Jun 10, 2024 | Bhanji Muna | Director | Form 4 sale | 3,870 | $79k | 14.3% | Routine | SEC |
| Jun 7, 2024 | Eastham Karin | Director | Form 4 sale | 2,500 | $52k | 7.0% | Routine | SEC |
| May 28, 2024 | Bhanji Muna | Director | Form 4 sale | 1,539 | $32k | 5.4% | Routine | SEC |
| Apr 1, 2024 | Eastham Karin | Director | Form 4 sale | 10,000 | $217k | 23.2% | No plan | SEC |
| Mar 1, 2024 | Jones Evan/ Fa | Director | Form 4 sale | 10,000 | $244k | 21.0% | No plan | SEC |
| Jul 19, 2023 | Jones Evan/ Fa | Director | Form 4 sale | 3,928 | $118k | 9.5% | No plan | SEC |
| Jul 19, 2023 | Jones Evan/ Fa | Director | Form 144 notice | 3,090 | $90k | Notice | SEC | |
| Jul 19, 2023 | Jones Evan/ Fa | Director | Form 144 notice | 838 | $25k | Notice | SEC | |
| Jul 18, 2023 | Bishop John L | Director | Form 4 sale | 20,000 | $605k | 37.6% | Routine | SEC |
| Jul 18, 2023 | Jones Evan/ Fa | Director | Form 4 sale | 52,809 | $1.6M | 57.9% | Unusual | SEC |
| Jul 18, 2023 | Jones Evan/ Fa | Director | Form 144 notice | 7,441 | $222k | Notice | SEC | |
| Jul 18, 2023 | Jones Evan/ Fa | Director | Form 144 notice | 2,324 | $69k | Notice | SEC | |
| Jul 17, 2023 | Jones Evan/ Fa | Director | Form 144 notice | 23,949 | $717k | Notice | SEC | |
| Jul 17, 2023 | Jones Evan/ Fa | Director | Form 144 notice | 19,095 | $571k | Notice | SEC | |
| Jul 10, 2023 | Anderson Bonnie H | Director | Form 144 notice | 68,000 | $1.6M | Notice | SEC | |
| Jun 16, 2023 | Bhanji Muna | Director | Form 4 sale | 5,893 | $156k | 17.1% | Routine | SEC |
| Jun 15, 2023 | Anderson Bonnie H | Director | Form 144 notice | 34,177 | $902k | Notice | SEC | |
| May 30, 2023 | Bhanji Muna | Director | Form 4 sale | 1,539 | $40k | 5.9% | No plan | SEC |
| May 30, 2023 | Bhanji Muna | Director | Form 144 notice | 7,432 | $190k | Notice | SEC | |
| Apr 14, 2023 | Anderson Bonnie H | Director | Form 4 sale | 34,000 | $749k | 44.3% | Unusual | SEC |
| Apr 14, 2023 | Anderson Bonnie H | Officer | Form 144 notice | 34,000 | $775k | Notice | SEC | |
| Mar 16, 2023 | Eastham Karin | Director | Form 4 sale | 18,750 | $427k | 44.4% | Unusual | SEC |
| Mar 15, 2023 | Anderson Bonnie H | Director | Form 4 sale | 34,000 | $774k | 38.7% | Unusual | SEC |
| Mar 15, 2023 | Anderson Bonnie H | Officer | Form 144 notice | 34,000 | $785k | Notice | SEC | |
| Feb 28, 2023 | Eastham Karin | Director | Form 4 sale | 10,000 | $250k | 29.9% | Unusual | SEC |
| Jan 17, 2023 | Anderson Bonnie H | Director | Form 4 sale | 34,000 | $896k | 35.1% | Unusual | SEC |
| Jan 11, 2023 | Anderson Bonnie H | Director | Form 4 sale | 63,247 | $1.6M | 50.1% | Unusual | SEC |
| Dec 14, 2022 | Jones Evan/ Fa | Director | Form 4 sale | 600 | $18k | 1.2% | Plan not stated | SEC |
| Dec 13, 2022 | Jones Evan/ Fa | Director | Form 4 sale | 1,667 | $51k | 3.2% | Plan not stated | SEC |
| Dec 6, 2022 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 1,023 | $28k | 1.5% | Plan not stated | SEC |
| Dec 1, 2022 | Anderson Bonnie H | Executive Chairwoman | Form 4 sale | 80,000 | $2.3M | 55.2% | Unusual | SEC |
| Nov 11, 2022 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 2 | $59 | 0.0% | Plan not stated | SEC |
| Nov 11, 2022 | Jones Evan/ Fa | Director | Form 4 sale | 6,000 | $181k | 10.3% | Plan not stated | SEC |
| Nov 4, 2022 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 1,023 | $26k | 1.5% | Plan not stated | SEC |
| Aug 8, 2022 | Anderson Bonnie H | Executive Chairwoman | Form 4 sale | 121,917 | $3.4M | 52.0% | Unusual | SEC |
| Aug 5, 2022 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 1,028 | $27k | 1.4% | Plan not stated | SEC |
| Jun 14, 2022 | Holstein Jens | Director | Form 4 sale | 8,720 | $142k | 81.3% | Unusual | SEC |
| Jun 8, 2022 | Gordon Kevin K | Director | Form 4 sale | 15,000 | $278k | 63.2% | Unusual | SEC |
| Mar 4, 2022 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 23,003 | $578k | 27.3% | Unusual | SEC |
| Dec 17, 2021 | Eastham Karin | Director | Form 4 sale | 5,000 | $225k | 36.4% | Unusual | SEC |
| Dec 7, 2021 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 15,357 | $579k | 24.3% | Plan not stated | SEC |
| Nov 1, 2021 | Eastham Karin | Director | Form 4 sale | 4,400 | $145M | 100.0% | Unusual | SEC |
| Sep 17, 2021 | Anderson Bonnie H | Executive Chairwoman | Form 4 sale | 2,600 | $130k | 1.2% | Plan not stated | SEC |
| Sep 10, 2021 | Anderson Bonnie H | Executive Chairwoman | Form 4 sale | 1,900 | $95k | 0.9% | Plan not stated | SEC |
| Sep 8, 2021 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 13,457 | $680k | 21.2% | Plan not stated | SEC |
| Aug 2, 2021 | Eastham Karin | Director | Form 4 sale | 4,400 | $193k | 50.0% | Unusual | SEC |
| Jun 23, 2021 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 4,375 | $174k | 7.8% | Plan not stated | SEC |
| Jun 4, 2021 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 9,081 | $315k | 14.9% | Plan not stated | SEC |
| May 3, 2021 | Eastham Karin | Director | Form 4 sale | 4,427 | $214k | 33.5% | Unusual | SEC |
| Mar 4, 2021 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 52,015 | $2.6M | 49.2% | Unusual | SEC |
| Feb 25, 2021 | Eastham Karin | Director | Form 4 sale | 6,250 | $379k | 100.0% | Unusual | SEC |
| Jan 13, 2021 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 18,541 | $946k | 8.3% | Plan not stated | SEC |
| Jan 12, 2021 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 91,459 | $4.6M | 31.0% | Unusual | SEC |
| Jan 4, 2021 | Gordon Kevin K | Director | Form 4 sale | 10,000 | $490k | 100.0% | Unusual | SEC |
| Dec 4, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 14,015 | $797k | 15.2% | Plan not stated | SEC |
| Nov 12, 2020 | Gordon Kevin K | Director | Form 4 sale | 10,000 | $471k | 100.0% | Unusual | SEC |
| Nov 11, 2020 | Ho Mark | Other | Form 4 sale | 13,875 | $624k | 42.1% | Unusual | SEC |
| Nov 6, 2020 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 21,250 | $923k | 22.2% | Plan not stated | SEC |
| Nov 5, 2020 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 6,406 | $261k | 7.9% | Plan not stated | SEC |
| Oct 8, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 50,000 | $1.9M | 18.5% | Unusual | SEC |
| Oct 6, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 2,500 | $88k | 3.1% | Plan not stated | SEC |
| Sep 10, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $618k | 8.3% | Plan not stated | SEC |
| Sep 4, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 7,027 | $219k | 8.1% | Plan not stated | SEC |
| Aug 31, 2020 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 56,443 | $1.9M | 43.1% | Unusual | SEC |
| Aug 21, 2020 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 1,400 | $50k | 1.8% | Plan not stated | SEC |
| Aug 3, 2020 | Jones Evan/ Fa | Director | Form 4 sale | 40,000 | $1.4M | 36.5% | Unusual | SEC |
| Jul 31, 2020 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 14,095 | $509k | 15.9% | Plan not stated | SEC |
| Jul 31, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 20,000 | $707k | 19.9% | Plan not stated | SEC |
| Jul 30, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 11,365 | $366k | 4.0% | Plan not stated | SEC |
| Jul 23, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 3,280 | $105k | 1.2% | Plan not stated | SEC |
| Jul 22, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 23,896 | $766k | 8.1% | Plan not stated | SEC |
| Jul 21, 2020 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 11,947 | $383k | 13.8% | Plan not stated | SEC |
| Jul 15, 2020 | Jones Evan/ Fa | Director | Form 4 sale | 30,000 | $868k | 21.5% | Plan not stated | SEC |
| Jul 13, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 16,738 | $496k | 17.2% | Plan not stated | SEC |
| Jul 13, 2020 | Epstein Robert S | Director | Form 4 sale | 10,000 | $297k | 100.0% | Unusual | SEC |
| Jul 6, 2020 | Kennedy Keith | COO / CFO | Form 4 sale | 86,424 | $2.4M | 41.9% | Unusual | SEC |
| Jun 10, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $531k | 6.8% | Plan not stated | SEC |
| Jun 3, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 10,786 | $283k | 11.8% | Plan not stated | SEC |
| May 18, 2020 | Cohen Fred E | Director | Form 4 sale | 40,000 | $1.1M | 100.0% | Unusual | SEC |
| May 11, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $533k | 6.8% | Plan not stated | SEC |
| Mar 10, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $504k | 7.2% | Plan not stated | SEC |
| Mar 3, 2020 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 32,881 | $835k | 28.8% | Unusual | SEC |
| Jan 16, 2020 | Jones Evan/ Fa | Director | Form 4 sale | 14,049 | $423k | 9.1% | Plan not stated | SEC |
| Jan 16, 2020 | Kennedy Keith | COO / CFO | Form 4 sale | 7,052 | $212k | 6.0% | Plan not stated | SEC |
| Jan 14, 2020 | Jones Evan/ Fa | Director | Form 4 sale | 5,000 | $143k | 3.2% | Plan not stated | SEC |
| Jan 10, 2020 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $577k | 14.5% | Plan not stated | SEC |
| Dec 27, 2019 | Kennedy Keith | COO / CFO | Form 4 sale | 400 | $12k | 0.4% | Plan not stated | SEC |
| Dec 17, 2019 | Jones Evan/ Fa | Director | Form 4 sale | 15,000 | $439k | 8.6% | Plan not stated | SEC |
| Dec 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $579k | 16.3% | Plan not stated | SEC |
| Dec 6, 2019 | Jones Evan/ Fa | Director | Form 4 sale | 5,951 | $179k | 3.3% | Plan not stated | SEC |
| Dec 6, 2019 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 17,938 | $539k | 21.6% | Plan not stated | SEC |
| Dec 6, 2019 | Kennedy Keith | COO / CFO | Form 4 sale | 33,151 | $995k | 23.2% | Plan not stated | SEC |
| Dec 5, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 32,803 | $964k | 41.2% | Unusual | SEC |
| Dec 3, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 15,327 | $406k | 24.6% | Plan not stated | SEC |
| Nov 27, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 3,697 | $109k | 7.2% | Plan not stated | SEC |
| Nov 26, 2019 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 17,938 | $512k | 21.5% | Plan not stated | SEC |
| Nov 25, 2019 | Kennedy Keith | COO / CFO | Form 4 sale | 18,757 | $525k | 14.6% | Plan not stated | SEC |
| Nov 18, 2019 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 19,571 | $493k | 23.0% | Plan not stated | SEC |
| Nov 15, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $501k | 16.2% | Plan not stated | SEC |
| Oct 22, 2019 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 16,091 | $443k | 19.7% | Plan not stated | SEC |
| Oct 22, 2019 | Kennedy Keith | COO / CFO | Form 4 sale | 1,243 | $35k | 1.1% | Plan not stated | SEC |
| Oct 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $196k | 7.2% | Plan not stated | SEC |
| Sep 16, 2019 | Hanna John Walter JR | Chief Commercial Officer | Form 4 sale | 18,593 | $477k | 22.1% | Plan not stated | SEC |
| Sep 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $196k | 7.1% | Plan not stated | SEC |
| Sep 4, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 15,327 | $388k | 24.4% | Plan not stated | SEC |
| Aug 28, 2019 | Jones Evan/ Fa | Director | Form 4 sale | 10,000 | $261k | 5.3% | Plan not stated | SEC |
| Aug 13, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 32,897 | $835k | 40.6% | Unusual | SEC |
| Aug 12, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $202k | 6.6% | Plan not stated | SEC |
| Aug 9, 2019 | Jones Evan/ Fa | Director | Form 4 sale | 15,000 | $396k | 7.3% | Plan not stated | SEC |
| Jul 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $230k | 6.3% | Plan not stated | SEC |
| Jun 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $211k | 6.3% | Plan not stated | SEC |
| May 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $184k | 7.7% | Plan not stated | SEC |
| May 6, 2019 | Hall Christopher M | President and COO | Form 4 sale | 115,000 | $2.9M | 80.0% | Unusual | SEC |
| Apr 11, 2019 | Hall Christopher M | President and COO | Form 4 sale | 80,000 | $2M | 73.6% | Unusual | SEC |
| Apr 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $203k | 7.7% | Plan not stated | SEC |
| Mar 11, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $160k | 7.2% | Plan not stated | SEC |
| Mar 4, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 17,625 | $357k | 26.6% | Unusual | SEC |
| Mar 4, 2019 | Treu Jesse I | Director | Form 4 sale | 1.1M | $21.4M | 100.0% | Unusual | SEC |
| Feb 28, 2019 | Jones Evan/ Fa | Director | Form 4 sale | 75,000 | $1.5M | 26.8% | Unusual | SEC |
| Feb 28, 2019 | Kennedy Giulia C | Chief Scientific & Med Officer | Form 4 sale | 37,375 | $764k | 43.1% | Unusual | SEC |
| Feb 26, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 20,000 | $419k | 20.7% | Plan not stated | SEC |
| Feb 11, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $145k | 9.5% | Plan not stated | SEC |
| Jan 10, 2019 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 25,500 | $390k | 25.0% | Unusual | SEC |
| Dec 10, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 8,000 | $97k | 13.2% | Plan not stated | SEC |
| Nov 12, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 23,305 | $313k | 30.7% | Unusual | SEC |
| Oct 31, 2018 | Hall Christopher M | President and COO | Form 4 sale | 40,000 | $540k | 55.2% | Unusual | SEC |
| Aug 27, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 6,000 | $72k | 10.2% | Plan not stated | SEC |
| Aug 9, 2018 | Hall Christopher M | President and COO | Form 4 sale | 20,000 | $240k | 38.1% | Unusual | SEC |
| Aug 2, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 14,950 | $172k | 22.2% | Plan not stated | SEC |
| Aug 1, 2018 | Treu Jesse I | Director | Form 4 sale | 500,000 | $5.4M | 96.7% | Unusual | SEC |
| Jul 24, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 50 | $575 | 0.1% | Plan not stated | SEC |
| Jul 24, 2018 | Hall Christopher M | President and COO | Form 4 sale | 10,000 | $110k | 23.6% | Plan not stated | SEC |
| Jul 23, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 6,000 | $61k | 10.2% | Plan not stated | SEC |
| Jul 6, 2018 | Hall Christopher M | President and COO | Form 4 sale | 50,000 | $499k | 60.6% | Unusual | SEC |
| Jun 25, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 6,000 | $56k | 10.2% | Plan not stated | SEC |
| Jun 19, 2018 | Hall Christopher M | President and COO | Form 4 sale | 20,000 | $180k | 38.1% | Unusual | SEC |
| Jun 12, 2018 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 12,000 | $96k | 18.6% | Plan not stated | SEC |
| Oct 20, 2017 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 16,000 | $151k | 61.5% | Unusual | SEC |
| Oct 2, 2017 | Hall Christopher M | President and COO | Form 4 sale | 20,000 | $180k | 50.0% | Unusual | SEC |
| Sep 25, 2017 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 6,000 | $51k | 37.5% | Unusual | SEC |
| Aug 28, 2017 | Jones Evan/ Fa | Director | Form 4 sale | 22,500 | $176k | 7.4% | Plan not stated | SEC |
| Aug 24, 2017 | Jones Evan/ Fa | Director | Form 4 sale | 40,000 | $315k | 11.7% | Plan not stated | SEC |
| May 16, 2017 | Treu Jesse I | Director | Form 4 sale | 2,226 | $18k | 9.8% | Plan not stated | SEC |
| Mar 21, 2017 | Anderson Bonnie H | Chairman and CEO | Form 4 sale | 5,000 | $45k | 33.3% | Unusual | SEC |
| Nov 25, 2015 | Jones Evan/ Fa | Director | Form 4 sale | 15,000 | $108k | 100.0% | Unusual | SEC |
| Jul 24, 2015 | Guyer Shelly D | Chief Financial Officer | Form 4 sale | 1,000 | $12k | 100.0% | Unusual | SEC |
| Jul 22, 2015 | Hall Christopher M | Chief Operating Officer | Form 4 sale | 2,500 | $30k | 100.0% | Unusual | SEC |
| Jun 26, 2015 | Guyer Shelly D | Chief Financial Officer | Form 4 sale | 1,000 | $12k | 100.0% | Unusual | SEC |
| Sep 10, 2014 | Hall Christopher M | Chief Commercial Officer | Form 4 sale | 1,000 | $12k | 100.0% | Unusual | SEC |
| Sep 9, 2014 | Jones Evan/ Fa | Director | Form 4 sale | 27,304 | $344k | 6.8% | Plan not stated | SEC |
| Aug 18, 2014 | Hall Christopher M | Chief Commercial Officer | Form 4 sale | 1,000 | $13k | 100.0% | Unusual | SEC |
| Jul 10, 2014 | Hall Christopher M | Chief Commercial Officer | Form 4 sale | 3,000 | $45k | 100.0% | Unusual | SEC |
| Jun 27, 2014 | Anderson Bonnie H | President and CEO | Form 4 sale | 1,000 | $18k | 100.0% | Unusual | SEC |
| Jun 23, 2014 | Hall Christopher M | Chief Commercial Officer | Form 4 sale | 2,000 | $34k | 100.0% | Unusual | SEC |
| Jun 23, 2014 | Anderson Bonnie H | President and CEO | Form 4 sale | 4,000 | $66k | 100.0% | Unusual | SEC |
| Jun 20, 2014 | Guyer Shelly D | Chief Financial Officer | Form 4 sale | 1,250 | $20k | 100.0% | Unusual | SEC |
| Jun 19, 2014 | Hall Christopher M | Chief Commercial Officer | Form 4 sale | 3,000 | $45k | 100.0% | Unusual | SEC |
| Jun 12, 2014 | Jones Evan/ Fa | Director | Form 4 sale | 16,650 | $251k | 3.9% | Plan not stated | SEC |
| Jun 9, 2014 | Jones Evan/ Fa | Director | Form 4 sale | 22,870 | $333k | 5.1% | Plan not stated | SEC |
| Jun 5, 2014 | Jones Evan/ Fa | Director | Form 4 sale | 28,248 | $405k | 5.9% | Plan not stated | SEC |
| May 30, 2014 | Jones Evan/ Fa | Director | Form 4 sale | 23,882 | $366k | 4.8% | Plan not stated | SEC |